Metabolic Syndrome, Type 2 Diabetes Mellitus
Conditions
Brief summary
This is a Phase 2, multi-center, double-blind, placebo-controlled study of the safety and effect of PBI-4050 at doses ranging from 400 mg to 1200 mg on relevant biomarkers in subjects with inadequately-controlled T2DMS on stable background antidiabetic therapy.
Detailed description
This Phase 2 study will be performed by 15 sites in Canada. The total duration of study participation for each subject is approximately 20 weeks and comprises 6 study visits A total of approximately 268 subjects will be enrolled in the study and randomly assigned to one of the following 4 treatment groups: * PBI-4050 400 mg * PBI-4050 800 mg * PBI-4050 1200 mg * Placebo All subjects will receive the assigned study drug for 12 weeks.
Interventions
DRUGPBI-4050
Soft gelatine capsule containing 200 mg of the active ingredient per capsule
OTHERPlacebo
Placebo soft gelatine capsule
Sponsors
Liminal BioSciences Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subject is 18 years of age or older. 2. Subject has signed written informed consent. 3. Subject has a clinical diagnosis of T2DM with an HbA1c level between ≥ 7.5% and ≤ 10%. 4. Subject has been receiving stable antidiabetic therapy (with or without basal insulin) for a minimum of 3 months before the screening visit. 5. Subject is able and willing to self-monitor blood glucose level at home. 6. Subject has a body mass index (BMI) of ≥ 27 kg/m2 and ≤ 45 kg/m2. 7. Subject has metabolic syndrome, having at least 3 of the 5 risk factors.
Exclusion criteria
1. Subject is using prandial insulin or pre-mixed insulin in addition to oral hypoglycaemic agents for blood glucose control. 2. Subject is taking basal insulin dose \> 1.0 U/kg/day. 3. Subject has recent or on-going infection requiring systemic treatment with an anti-infective agent within 30 days before screening. 4. Subject has a history of pancreatitis or diabetic ketoacidosis. 5. Subject has had at least one episode of severe hypoglycaemia in the past 12 months. 6. Subject has evidence of significant cardiovascular disease within 3 months before screening. 7. Subject has an estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2. 8. Subject has uncontrolled hypertension. 9. Subject has a diagnosis of rheumatic or inflammatory disease; or other autoimmune or inflammatory disease. 10. Subject is concurrently taking and plans to routinely continue taking anti-inflammatory medications during the study. 11. Subject is currently using medications for the indication of (or at the doses indicated for) weight loss. 12. Subject has significantly elevated liver enzyme levels. 13. History of malignancy of any organ system, treated or untreated, within the past 5 years other than basal or squamous cell skin cancer. 14. Subject has a history of chronic alcohol or other substance abuse. 15. Subject has a history of an allergic reaction to PBI-4050 or any of its excipients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety of PBI-4050 400 mg, 800 mg, and 1200 mg as assessed by the number of subjects with abnormal laboratory values and/or adverse events that are related to treatment | 4 months | Number of subjects with abnormal laboratory values and/or adverse events that are related to treatment |
| To evaluate the efficacy of PBI-4050 400 mg, 800 mg, and 1200 mg | 3 months | Change from baseline on HbA1c levels |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline on diabetic biomarkers | 3 months | % reduction and/or increase of diabetic biomarkers such as fasting glucose, fasting insulin, fasting C-peptide |
| Change from baseline on pro-inflammatory/inflammatory biomarkers | 3 months | % reduction and/or increase of biomarkers such as IL-6, IL-18, adiponectin |
| To evaluate the effect of PBI-4050 on frequency of hypoglycaemia events | 3 months | Frequency of hypoglycaemia events |
Countries
Canada
Outcome results
None listed